{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:37:11Z","timestamp":1791041831238,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clcc.2022.01.007","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T11:59:33Z","timestamp":1642679973000},"page":"e152-e161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World"],"prefix":"10.1016","volume":"21","author":[{"given":"Qi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mifen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanshuo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-3255","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2022.01.007_bib0001","doi-asserted-by":"crossref","unstructured":"Siegel RA-O, Miller KA-O, Fuchs HE, Jemal A. Cancer Statistics, 2021.","DOI":"10.3322\/caac.21654"},{"key":"10.1016\/j.clcc.2022.01.007_bib0002","unstructured":"Van Cutsem E, Cervantes A, Adam R, et\u00a0al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer."},{"key":"10.1016\/j.clcc.2022.01.007_bib0003","unstructured":"Grothey A, Van Cutsem E Fau - Sobrero A, Sobrero A Fau - Siena S, et\u00a0al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial."},{"key":"10.1016\/j.clcc.2022.01.007_bib0004","unstructured":"Li J, Qin S, Xu R, et\u00a0al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial."},{"key":"10.1016\/j.clcc.2022.01.007_bib0005","unstructured":"FDA approves regorafenib (Stivarga) for metastatic colorectal cancer."},{"key":"10.1016\/j.clcc.2022.01.007_bib0006","unstructured":"Wilhelm SM, Dumas J Fau - Adnane L, Adnane L Fau - Lynch M, et\u00a0al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity."},{"key":"10.1016\/j.clcc.2022.01.007_bib0007","unstructured":"Li J, Qin S, Xu RH, et\u00a0al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial."},{"key":"10.1016\/j.clcc.2022.01.007_bib0008","unstructured":"Shirley M. Fruquintinib: First Global Approval."},{"key":"10.1016\/j.clcc.2022.01.007_bib0009","unstructured":"Mayer RJ, Van Cutsem E Fau - Falcone A, Falcone A Fau - Yoshino T, et\u00a0al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer."},{"key":"10.1016\/j.clcc.2022.01.007_bib0010","unstructured":"Xu J, Kim TW, Shen L, et\u00a0al. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine\/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study."},{"key":"10.1016\/j.clcc.2022.01.007_bib0011","unstructured":"Zhang Q, Wang Q, Wang X, Li J, Shen L, Peng ZA-O. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?"},{"key":"10.1016\/j.clcc.2022.01.007_bib0012","unstructured":"Jing ZA-OX, Rui Z, Binglan Z. A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis."},{"key":"10.1016\/j.clcc.2022.01.007_bib0013","unstructured":"Chen J, Wang J, Lin H, Peng Y. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials."},{"key":"10.1016\/j.clcc.2022.01.007_bib0014","unstructured":"Gao ZA-O, Cao C, Bao Y, Fan Y, Chen G, Fu PA-O. Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer."},{"key":"10.1016\/j.clcc.2022.01.007_bib0015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2017.35.4_suppl.721","article-title":"Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC)","volume":"35","author":"Komatsu","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.01.007_bib0016","unstructured":"Yamaguchi K, Komatsu Y, Satoh T, et\u00a0al. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting."},{"key":"10.1016\/j.clcc.2022.01.007_bib0017","unstructured":"Masuishi T, Taniguchi H, Hamauchi S, et\u00a0al. Regorafenib Versus Trifluridine\/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison."},{"key":"10.1016\/j.clcc.2022.01.007_bib0018","unstructured":"Adenis A, de la Fouchardiere C, Paule B, et\u00a0al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program."},{"key":"10.1016\/j.clcc.2022.01.007_bib0019","unstructured":"Kopeckova K, Buchler T, Bortlicek Z, et\u00a0al. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry."},{"key":"10.1016\/j.clcc.2022.01.007_bib0020","unstructured":"Shitara K, Yamanaka T, Denda T, et\u00a0al. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients."},{"key":"10.1016\/j.clcc.2022.01.007_bib0021","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/jco.2015.33.3_suppl.678","article-title":"Efficacy of chemotherapy after treatment with regorafenib in metastatic colorectal cancer (mCRC)","volume":"33","author":"Kidd","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.01.007_bib0022","unstructured":"Lu CY, Yeh YS, Huang CW, Ma CJ, Yu FJ, Wang JY. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping."},{"key":"10.1016\/j.clcc.2022.01.007_bib0023","unstructured":"Marks EI, Tan C, Zhang J, et\u00a0al. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy."},{"key":"10.1016\/j.clcc.2022.01.007_bib0024","unstructured":"Xu J, Xu RH, Qin S, et\u00a0al. Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial."},{"key":"10.1016\/j.clcc.2022.01.007_bib0025","unstructured":"Yeh KH, Yang TS, Hsu TC, et\u00a0al. Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan."},{"key":"10.1016\/j.clcc.2022.01.007_bib0026","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s10637-014-0154-x","article-title":"Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations","volume":"33","author":"Yoshino","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clcc.2022.01.007_bib0027","unstructured":"Metges JA-O, Genet D, Tougeron DA-O, et\u00a0al. Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort."},{"key":"10.1016\/j.clcc.2022.01.007_bib0028","unstructured":"Dane FA-OX, Ozgurdal K, Yal\u00e7\u0131n \u015e, et\u00a0al. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study."},{"key":"10.1016\/j.clcc.2022.01.007_bib0029","unstructured":"Bekaii-Saab TS, Ou FS, Ahn DH, et\u00a0al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study."},{"key":"10.1016\/j.clcc.2022.01.007_bib0030","unstructured":"Suzuki T, Sukawa Y, Imamura CK, et\u00a0al. A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)."}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282200007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282200007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:08:29Z","timestamp":1761520109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153300282200007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S153300282200007X"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2022.01.007","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2022.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}